SGMO— SANGAMO THERAPEUTICS, INC

MaterialsBiotechnology$46M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	$39.6M-31.6%	$57.8M-67.2%	$176.2M-99.8%	$111.30B
Research and development	$112.7M+1.0%	$111.5M-52.4%	$234.1M-99.9%	$249.90B
General and administrative	$34.9M-22.0%	$44.7M-26.9%	$61.2M-99.9%	$62.68B
Impairment of long-lived assets	$13.2M+139.7%	$5.5M-91.6%	$65.5M	$0
Total operating expenses	$160.8M-0.6%	$161.8M-64.1%	$450.2M-99.9%	$312.58B
Loss from operations	-$121.2M-16.6%	-$104.0M+62.1%	-$274.0M+99.9%	-$201.28B
Interest income	$1.3M-13.9%	$1.5M	—	—
Other (expense) income, net	-$3.6M-181.9%	$4.3M	—	—
Loss before income taxes	-$123.5M-25.9%	-$98.1M+62.7%	-$262.9M+99.9%	-$191.85B
Income tax benefit	-$568K-240.1%	-$167K+96.7%	-$5.1M-101.2%	$429.0M
Net loss	-$122.9M-25.5%	-$97.9M+62.0%	-$257.8M+99.9%	-$192.28B
Basic net loss per share (in dollars per share)	-$440.00+10.2%	-$490.00+66.9%	-$1480.00-18.4%	-$1250.00
Diluted net loss per share (in dollars per share)	-$440.00+10.2%	-$490.00+66.9%	-$1480.00-18.4%	-$1250.00
Shares used in computing basic net loss per share (in shares)	$280193000.00+38.9%	$201699000.00+15.6%	$174444000.00+13.0%	$154345000.00
Shares used in computing diluted net loss per share (in shares)	$280193000.00+38.9%	$201699000.00+15.6%	$174444000.00+13.0%	$154345000.00

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.